活血化瘀法在恶性肿瘤治疗中的应用
|
摘要
探讨活血化瘀在恶性肿瘤辨治中的应用方法。认为恶性肿瘤之病理变化与血瘀状态及瘀血产物密切相关,临证运用活血化瘀法,当与病机相应,重成瘀之因;与病程相应,明瘀成之时;与病位相应,知生瘀之处;与病理产物相应,晓瘀生之度。活血方药之用,以扶正为先,以正本清源为治;化瘀治法之用,中病即止,时时养血,以防瘀血再生。
This paper discusses the application of the method for promoting blood circulation and removing blood stasis in the differentiation and treatment of malignant tumors. The pathological changes of malignant tumor are closely related to the state of blood stasis and the products originated from blood stasis. The method should be used when it is appropriate to the pathogenesis,to the course of disease,to the site of disease and to the pathological products. Physicians should focus on the cause of blood stasis,know the forming time,recognize the site and understand the degree of blood stasis in treating the disease. The prescription of promoting blood circulation should be used to strengthen healthy qi first for treating the root of the disease and be stopped using when it works. Meanwhile,the method of nourishing blood is often used to prevent blood stasis from occurring again.
This paper discusses the application of the method for promoting blood circulation and removing blood stasis in the differentiation and treatment of malignant tumors. The pathological changes of malignant tumor are closely related to the state of blood stasis and the products originated from blood stasis. The method should be used when it is appropriate to the pathogenesis,to the course of disease,to the site of disease and to the pathological products. Physicians should focus on the cause of blood stasis,know the forming time,recognize the site and understand the degree of blood stasis in treating the disease. The prescription of promoting blood circulation should be used to strengthen healthy qi first for treating the root of the disease and be stopped using when it works. Meanwhile,the method of nourishing blood is often used to prevent blood stasis from occurring again.
引文
[1]WALKER A J,CARD T R,WEST J,et al.Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases[J].Eur J Cancer,2013,49(6):1404-1413.
[2]ELALAMY I,VERDY E,GEROTZIAFAS G,et al.Pathogenesis of venous thromboembolic disease in cancer[J].Pathol Biol,2008,56(4):184-194.
[3]黄霓,游金辉.VEGF、p53在恶性肿瘤骨转移中相关机制的研究进展[J].医学综述,2018,24(11):2160-2164.
[4]刘宣,王炎,李丹光,等.丹参酮ⅡA对COX-2激活Wnt/β-catenin信号通路介导的人肠癌细胞VEGF表达的调控作用[J].中华中医药杂志,2013,28(1):108-112.
[5]SANDLER A,GRAY R,PERRY M C,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl JMed,2006,355(24):2542-2550.
[6]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.
[7]刘磊,张光霁,楼招欢,等.丹参有效成分防治恶性肿瘤作用机制的研究进展[J].中华中医药杂志,2018,33(6):2472-2475.
[8]韩海英,张培彤,王耀焓,等.川芎嗪联合丹参酮ⅡA对人肺巨细胞癌PG-BE1、PG-LH7细胞增殖、黏附及侵袭的影响[J].中国肿瘤,2016,25(9):728-733.
[9]金忠明,洪伟鹏,黄民.丹参在逆转肿瘤耐药及化疗增敏中的研究进展[J].中国药理学通报,2018,34(7):889-891.
[10]任陈,杜莎莎.丹参酮ⅡA减轻海马神经元细胞的放射性损伤[J].广东医学,2018,39(6):807-810.
[11]吴依芬,贾筠,周迎春,等.补阳还五汤对曲妥珠单抗干预后的心肌细胞H9C2的调控作用[J].广州中医药大学学报,2015,32(3):475-480.
[12]郑华,秦霞,宋慧,等.基于H-NMR的当归四逆汤抗凝血作用的代谢组学研究[J].中国中药杂志,2015,40(20):4088-4093.
[13]铁明慧,张颖,王科.鳖甲煎丸对肝癌皮下转移瘤小鼠肿瘤新生血管及微环境的影响[J].中医杂志,2018,58(4):325-328.
[14]吴昊,魏吉红,郑瑾,等.论阳虚与肿瘤形成的关系[J].中华中医药杂志,2017,32(3):969-971.
[15]陈嘉斌,柴可群,陈淼,等.柴可群辨治结、直肠癌的学术思想及临诊经验探析[J].中华中医药杂志,2015,30(11):3956-3959.
[16]柴可群,陈嘉斌,徐国暑.基于病证结合论中医辨治肿瘤四则四法[J].中医杂志,2016,57(2):111-114.
[17]李军,王庆学,王镜辉,等.肝主疏泄理论对中医药防治肿瘤的意义[J].中医杂志,2018,59(19):1705-1707.
[2]ELALAMY I,VERDY E,GEROTZIAFAS G,et al.Pathogenesis of venous thromboembolic disease in cancer[J].Pathol Biol,2008,56(4):184-194.
[3]黄霓,游金辉.VEGF、p53在恶性肿瘤骨转移中相关机制的研究进展[J].医学综述,2018,24(11):2160-2164.
[4]刘宣,王炎,李丹光,等.丹参酮ⅡA对COX-2激活Wnt/β-catenin信号通路介导的人肠癌细胞VEGF表达的调控作用[J].中华中医药杂志,2013,28(1):108-112.
[5]SANDLER A,GRAY R,PERRY M C,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].N Engl JMed,2006,355(24):2542-2550.
[6]胡彬彬,陈宝清,卢铀.贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展[J].中国肿瘤临床,2017,44(3):129-135.
[7]刘磊,张光霁,楼招欢,等.丹参有效成分防治恶性肿瘤作用机制的研究进展[J].中华中医药杂志,2018,33(6):2472-2475.
[8]韩海英,张培彤,王耀焓,等.川芎嗪联合丹参酮ⅡA对人肺巨细胞癌PG-BE1、PG-LH7细胞增殖、黏附及侵袭的影响[J].中国肿瘤,2016,25(9):728-733.
[9]金忠明,洪伟鹏,黄民.丹参在逆转肿瘤耐药及化疗增敏中的研究进展[J].中国药理学通报,2018,34(7):889-891.
[10]任陈,杜莎莎.丹参酮ⅡA减轻海马神经元细胞的放射性损伤[J].广东医学,2018,39(6):807-810.
[11]吴依芬,贾筠,周迎春,等.补阳还五汤对曲妥珠单抗干预后的心肌细胞H9C2的调控作用[J].广州中医药大学学报,2015,32(3):475-480.
[12]郑华,秦霞,宋慧,等.基于H-NMR的当归四逆汤抗凝血作用的代谢组学研究[J].中国中药杂志,2015,40(20):4088-4093.
[13]铁明慧,张颖,王科.鳖甲煎丸对肝癌皮下转移瘤小鼠肿瘤新生血管及微环境的影响[J].中医杂志,2018,58(4):325-328.
[14]吴昊,魏吉红,郑瑾,等.论阳虚与肿瘤形成的关系[J].中华中医药杂志,2017,32(3):969-971.
[15]陈嘉斌,柴可群,陈淼,等.柴可群辨治结、直肠癌的学术思想及临诊经验探析[J].中华中医药杂志,2015,30(11):3956-3959.
[16]柴可群,陈嘉斌,徐国暑.基于病证结合论中医辨治肿瘤四则四法[J].中医杂志,2016,57(2):111-114.
[17]李军,王庆学,王镜辉,等.肝主疏泄理论对中医药防治肿瘤的意义[J].中医杂志,2018,59(19):1705-1707.